Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection
Status:
Completed
Trial end date:
2019-11-20
Target enrollment:
Participant gender:
Summary
This study aimed to evaluate the safety, tolerability, and pharmacokinetics of maraviroc in
infants at risk for mother-to-child HIV transmission, and to determine an appropriate dose of
maraviroc during the first six weeks of life.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) GlaxoSmithKline ViiV Healthcare